ArticlePharmacology, biochemistry, and behavior2019
The α2,3-selective potentiator of GABA
Open access · greenAbstract read
In one paragraph
Article in Pharmacology, biochemistry, and behavior, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Effects of TPA023B, an α2/3/5GABAPsychopharmacology · 2026Article
- Antinociceptive Effects ofThe Journal of pharmacology and experimental therapeutics · 2024Article
- Attenuation of Streptozotocin-Induced Diabetic Neuropathic Allodynia by Flavone Derivative Through Modulation of GABA-ergic Mechanisms and Endogenous Biomarkers.Neurochemical research · 2024Article
- New Imidazodiazepine Analogue, 5-(8-Bromo-6-(pyridin-2-yl)-4ACS chemical neuroscience · 2024Article
- Article
- New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development.CNS drugs · 2023Review
- Therapeutic effects of KRM-II-81, positive allosteric modulator for α2/3 subunit containing GABAFrontiers in pharmacology · 2023Article
- Hydrochloride Salt of the GABAkine KRM-II-81.ACS omega · 2022Article
- GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAPharmacology & therapeutics · 2022Review
- Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3-selective GABAkine KRM-II-81.Biopharmaceutics & drug disposition · 2022Article
- Synthesis and Pharmacological Evaluation of Novel 2,3,4,5-tetrahydro[1,3]diazepino[1,2-Molecules (Basel, Switzerland) · 2021Article
- 5-International journal of molecular sciences · 2021Article
- A Structure-Activity Relationship Comparison of Imidazodiazepines Binding at Kappa, Mu, and Delta Opioid Receptors and the GABAMolecules (Basel, Switzerland) · 2020Article
- The Positive Allosteric Modulator ofThe Journal of pharmacology and experimental therapeutics · 2020Article
- Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain.Frontiers in pharmacology · 2020Review
- Design, synthesis and characterization of novel gamma‑aminobutyric acid type A receptor ligands.ARKIVOC : free online journal of organic chemistry · 2020Article
- KCC2 receptor upregulation potentiates antinociceptive effect of GABAAR agonist on remifentanil-induced hyperalgesia.Molecular painArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 7 institutions in 1 country.
J M WitkinThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA; Department of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA; Laboratory of Antiepileptic Drug Discovery, Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: witkinconsult@gmail.com.
R CerneThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
P G DavisMillsaps College, Jackson, MS, USA.
K B FreemanDepartment of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA.
J M do CarmoDepartment of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA.
J K RowlettDepartment of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA.
K R MethukuDepartment of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
A OkunThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
S D GleasonThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
X LiThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
M J KrambisThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
M PoeDepartment of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
G LiDepartment of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
J M SchkeryantzThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
R JahanDepartment of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
L YangThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
W GuoThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
L K GolaniDepartment of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
W H AndersonThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
J T CatlowThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
T M JonesThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
F PorrecaDepartment of Pharmacology, University of Arizona, Tucson, AZ, USA.
J L SmithLaboratory of Antiepileptic Drug Discovery, Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
K L KnoppThe Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
J M CookDepartment of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
Eli Lilly (United States) · USUniversity of Wisconsin–Milwaukee · USJackson Memorial Hospital · USUniversity of Mississippi Medical Center · USIndiana University School of MedicineMillsaps College · USNeurological Surgery · US
Funding
SELECTIVE ANXIOLYTICS VIA BZR SUBTYPE SPECIFIC LIGANDSR01MH046851 · NIMH · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 1991 to 2010
$4.4MDevelopment of new drugs for asthma by targeting GABA(A) receptors in the lungR01HL118561 · NHLBI · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2014 to 2017
$2.0MDesign of New Therapeutic Agents to Treat SchizophreniaR01MH096463 · NIMH · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2013 to 2017
$1.9MSynthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic PainR01NS076517 · NINDS · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2012 to 2015
$1.3MNHLBI NIH HHS R01 HL118561NIMH NIH HHS R01 MH046851NIMH NIH HHS R01 MH096463NINDS NIH HHS R01 NS076517
Abstract
Clinical evidence indicates that positive allosteric modulators (PAMs) of GABA
Indexed as
Drug SynergismPain MeasurementAdjuvants, AnesthesiaAdministration, OralAlprazolamAnalgesicsAnimalsBehavior, AnimalDiazepamDose-Response Relationship, DrugFormaldehydeGABA ModulatorsLigationMaleNeuralgiaOxazolesAdjuvants, AnesthesiaAlprazolamAnalgesicsDiazepamFormaldehydeGABA ModulatorsKRM-II-81OxazolesReceptors, GABA-A
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.